More on CGEN
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.08 |
|
|||
| Open | $2.08 | ||||
| 52 Wk High | $7.79 | ||||
| 52 Wk Low | $4.32 | ||||
| Day High | $2.09 | ||||
| Day Low | $1.93 | ||||
| P/E | N/A | ||||
| EPS | $-0.36 | ||||
| Volume | 173,436 | ||||
- Compugen (CGEN) Reiterated at Buy by Stifel After Overview of COM701 Trial
- Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference
- Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026
- Form 6-K COMPUGEN LTD For: Sep 10
- Daiichi Sankyo and AstraZeneca start phase 3 urothelial cancer trial
- TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
- H.C. Wainwright Reiterates Buy Rating on Compugen (CGEN)
- Form 6-K COMPUGEN LTD For: Aug 03
- Compugen (CGEN) Tops Q2 EPS by 1c
- Form 6-K COMPUGEN LTD For: Jun 30
Entities mentioned with CGEN
- Earnings | View Related Stories »
- FDA | View Related Stories »
- 13G | View Related Stories »
- Stifel | View Related Stories »
- ARK | View Related Stories »
- Jefferies & Co | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
